NCT04388384 2025-08-06
ELEANOR
Pierre Fabre Pharma GmbH
Completed
Clinical Trials
15 trialsNCT04366713 2023-02-10
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
Puma Biotechnology, Inc.
Phase 2 Completed
NCT05491057 2022-08-08
Treatment Patterns of Neratinib in HER2+ EBC in China
Pierre Fabre Medicament
Not yet recruiting
NCT02400476 2022-05-06
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00878709 2021-06-11
ExteNET
Puma Biotechnology, Inc.
Phase 3 Completed
NCT00146172 2018-09-17
Study Evaluating HKI-272 in Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00741260 2018-09-05
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00915018 2018-08-22
NEFERTT
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00300781 2018-08-14
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00706030 2018-08-09
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00445458 2018-07-26
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00398567 2018-07-24
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00366600 2017-09-11
Study Evaluating HKI-272 Administered to Healthy Subjects
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00708903 2012-05-14
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
Puma Biotechnology, Inc.
Phase 1 Completed